Eris Lifescience reports a year-over-year increase in Q4 revenue, reaching ₹757 crore, up from ₹705 crore. The company's profit margins also improved slightly to 36.2%. shareholders can expect an interim dividend of ₹5.21 per share.

Eris Lifesciences projects a robust 18-20% revenue increase for fiscal year 2022, signaling a strong and positive trajectory ahead.

Eris Lifesciences has experienced a substantial 111% increase in its EBITDA, reaching Rs. 29.7 crore year-on-year. The company anticipates the introduction of an obesity-focused product line in the fiscal year 2026-2027 (FY27).

According to MarketsMojo, Eris Lifesciences receives a 'Sell' recommendation due to its questionable valuation, financial performance, and technical prospects, suggesting potential investment risks for investors.

Eris Lifesciences announced an interim dividend of INR 7.21 per share for the fiscal year 2026, with the record date set on May 29, 2026, and payments scheduled for June 19, 2026. The company's profit for FY26 reached INR 647.51 crores.

Eris Lifesciences saw a significant jump in Q4 EBITDA, reaching ₹2.73B, marking a year-on-year growth from ₹2.52B. Moreover, the company managed to improve its EBITDA margin to 36.2%, compared to 35.8% last year, demonstrating strong profitability.

The Nifty is currently trading below the 23,550 mark, with media stocks experiencing a drop in a subdued market session. However, Eris Lifesciences bucked the trend and is one of the few stocks trading higher today, without any specific updates.

Credit rating agency Ind-Ra has confirmed Eris Lifesciences' long-term rating at IND AA Stable, indicating a stable outlook for the company. The decision is based on Eris Lifesciences' solid performance, strategic acquisitions, and robust credit metrics.

Eris Lifesciences experienced a 0.9% dip in share price following non-compliance issues with HALMED at Swiss Parenterals facilities. The company plans to address the matter through GMP remediation, and although this may impact business minimally, shares closed at ₹1,432.40 on NSE for the day.

Eris Lifesciences encountered a setback in its European operations due to a procedural non-compliance issue identified during an inspection by HALMED at their Ahmedabad units in March 2026. The company is now working on corrective actions and arranging for a follow-up inspection, which may cause delays in commercializing products in the EU market.

Eris Life's CDMO expansion might experience setbacks due to pending issues, potentially leading to reduced revenues in the near term. The revenue decline is partly attributed to delays in their CDMO ramp-up and market challenges.

Eris Lifesciences recently executed a significant trade worth INR 22.35 crore, with the deal involving 152,561 shares priced at INR 1,465 each.

Eris Lifesciences has officially acquired Velbiom Probiotics as announced, following the initial deal update from March 20, 2026. The transaction's completion was confirmed and a filing was made for public records.